Takeda Canada Inc. Concludes Letter of Intent (LOI) With the Pan-Canadian Pharmaceutical Alliance (PCPA) for LIVTENCITY (Maribavir) for the Treatment of Adults With a Post-Transplant Cytomegalovirus (CMV) Infection
Takeda Canada Inc. Concludes Letter of Intent (LOI) With the Pan-Canadian Pharmaceutical Alliance (PCPA) for LIVTENCITY (Maribavir) for the Treatment of Adults With a Post-Transplant Cytomegalovirus (CMV) Infection
Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) for LIVTENCITY (maribavir) for the treatment for adults with a post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 With the LOI stage now complete, the provinces and territories may proceed in initiating their individual processes of listing LIVTENCITY as part of their formularies.
武田加拿大公司（“武田”）很高興地宣佈，它已經完成了與泛加拿大製藥聯盟（PCPA）的談判，該意向書（LOI）旨在治療移植後鉅細胞病毒（CMV）感染/疾病、對一種或多種先前抗病毒療法具有耐藥性（有或沒有基因型耐藥性）的成年人的LIVTENCITY（maribavir）。1 隨着意向書階段的完成，各省和地區可以着手啓動將LIVTENCITY列爲其公式一部分的個別程序。
譯文內容由第三人軟體翻譯。